|
Mar 20
|
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
|
|
Mar 8
|
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
|
|
Mar 4
|
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Dec 26
|
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
|
|
Nov 29
|
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
|
|
Aug 11
|
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
|
|
Apr 26
|
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board
|